Smith & Nephew SNATS (SNN) Stock Price, News & Analysis

Company Overview

Smith & Nephew plc (NYSE: SNN) is a global medical technology company specializing in the design, development and commercialization of advanced surgical devices and wound management solutions. The business serves healthcare professionals in orthopaedic reconstruction, trauma and extremities, sports medicine, ear, nose and throat (ENT), and advanced wound care. Its product portfolio includes hip and knee joint implants, arthroscopic instruments, biologic therapies for tissue repair and regenerative medicine dressings for acute and chronic wounds.

The company’s orthopaedic reconstruction division offers both cemented and cementless hip and knee replacement systems designed to improve patient mobility and long-term implant performance. In the sports medicine and ENT segment, Smith & Nephew markets a range of minimally invasive surgical tools and endoscopic technologies used in soft tissue repair, joint preservation and sinus and nasal procedures. Its advanced wound management unit provides bio-engineered skin substitutes, silver-based antimicrobial dressings and negative pressure wound therapy devices aimed at accelerating healing in diabetic foot ulcers, burns and other complex wounds.

Founded in 1856 by Thomas James Smith in Hull, England, Smith & Nephew has evolved into a multinational organization headquartered in London. The company maintains research and development centers across Europe and North America and distributes its products in more than 100 countries throughout Europe, the Americas, Asia Pacific, the Middle East and Africa. Over more than 160 years of operation, Smith & Nephew has established strategic partnerships with hospitals, clinics and research institutions to drive clinical innovation and expand its global footprint.

Under the leadership of Chief Executive Officer Roland Diggelmann, Smith & Nephew continues to invest in next-generation technologies aiming to enhance patient outcomes and support value-based healthcare delivery. The company’s ongoing clinical trials and regulatory submissions reflect its commitment to addressing unmet medical needs in musculoskeletal care and wound healing. With a focus on emerging markets and digital surgery platforms, Smith & Nephew seeks to sustain its position as a leader in advanced medical solutions.

Key Stats

• Today's Range: $29.84 to $30.08
• 50-Day Range: $28.01 to $31.05
• 52-Week Range: $23.69 to $31.72
• Volume: 276,646 shs
• Average Volume: 879,713 shs
• Market Capitalization: $13.11 billion
• P/E Ratio: 13.84
• Dividend Yield: 2.97%
• Price Target: $28.00
• Consensus Rating: Hold

Smith & Nephew SNATS Stock Analysis - MarketRank™

Smith & Nephew SNATS scored higher than 61% of companies evaluated by MarketBeat, and ranked 472nd out of 937 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.0 / 5
• Analyst Rating: Hold

Consensus Rating

Smith & Nephew SNATS has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 6 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Smith & Nephew SNATS has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 4.4 / 5
• Proj. Earnings Growth: 18.34%

Earnings Growth

Earnings for Smith & Nephew SNATS are expected to grow by 18.34% in the coming year, from $1.69 to $2.00 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Smith & Nephew SNATS is 13.87, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 26.48.

Price to Earnings Ratio vs. Sector

The P/E ratio of Smith & Nephew SNATS is 13.87, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 28.24.

Price to Earnings Growth Ratio

Smith & Nephew SNATS has a PEG Ratio of 0.90. PEG Ratios below 1 indicate that a company could be undervalued.

Price to Book Value per Share Ratio

Smith & Nephew SNATS has a P/B Ratio of 2.49. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.59% of the float of Smith & Nephew SNATS has been sold short.

Short Interest Ratio / Days to Cover

Smith & Nephew SNATS has a short interest ratio ("days to cover") of 2.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Smith & Nephew SNATS has recently increased by 4.84%, indicating that investor sentiment is decreasing.

Dividend

• Score: 2.5 / 5
• Dividend Strength: Moderate

Dividend Yield

Smith & Nephew SNATS pays a meaningful dividend of 3.05%, higher than the bottom 25% of all stocks that pay dividends.

Dividend Growth

Smith & Nephew SNATS does not have a long track record of dividend growth.

Dividend Coverage

The dividend payout ratio of Smith & Nephew SNATS is 41.20%. This payout ratio is at a healthy, sustainable level, below 75%.

Dividend Sustainability

Based on earnings estimates, Smith & Nephew SNATS will have a dividend payout ratio of 44.50% next year. This indicates that Smith & Nephew SNATS will be able to sustain or increase its dividend.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.59% of the float of Smith & Nephew SNATS has been sold short.

Short Interest Ratio / Days to Cover

Smith & Nephew SNATS has a short interest ratio ("days to cover") of 2.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Smith & Nephew SNATS has recently increased by 4.84%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 2.8 / 5
• News Sentiment: 1.07

News Sentiment

Smith & Nephew SNATS has a news sentiment score of 1.07. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.96 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Smith & Nephew SNATS this week, compared to 4 articles on an average week.

MarketBeat Follows

1 people have added Smith & Nephew SNATS to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Smith & Nephew SNATS insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 1.00% of the stock of Smith & Nephew SNATS is held by insiders.

Percentage Held by Institutions

Only 25.64% of the stock of Smith & Nephew SNATS is held by institutions.

SNN Stock Analysis - Frequently Asked Questions

How have SNN shares performed this year?

Smith & Nephew SNATS's stock was trading at $24.58 on January 1st, 2025. Since then, SNN stock has increased by 21.9% and is now trading at $29.9540.

How were Smith & Nephew SNATS's earnings last quarter?

Smith & Nephew SNATS, Inc. (NYSE:SNN) posted its earnings results on Monday, November, 17th. The medical equipment provider reported $0.98 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.39 by $0.59.

Who are Smith & Nephew SNATS's major shareholders?

Smith & Nephew SNATS's top institutional investors include Scharf Investments LLC (0.48%), Oliver Luxxe Assets LLC (0.04%), Eagle Global Advisors LLC (0.01%) and Wealth Enhancement Advisory Services LLC (0.01%).

How do I buy shares of Smith & Nephew SNATS?

Shares of SNN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Smith & Nephew SNATS own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Smith & Nephew SNATS investors own include JPMorgan Chase & Co. (JPM), Johnson & Johnson (JNJ), PepsiCo (PEP), Taiwan Semiconductor Manufacturing (TSM), McDonald's (MCD), Sanofi (SNY) and Alibaba Group (BABA).

Company Calendar

• Last Earnings: 11/17/2014
• Record date for 5/28 Dividend: 3/28/2025
• Ex-Dividend for 5/28 Dividend: 3/28/2025
• Dividend Payable: 5/28/2025
• Today: 7/17/2025
• Next Earnings (Estimated): 8/05/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: MED PRODUCTS
• Sub-Industry: Medical Equipment
• Current Symbol: NYSE:SNN
• CIK: 845982
• Web: www.smith-nephew.com
• Phone: 441923477100
• Fax: 44-20-7930-3353
• Employees: 17,349
• Year Founded: 1856

Price Target and Rating

• Average Price Target for Smith & Nephew SNATS: $28.00
• High Price Target: $28.00
• Low Price Target: $28.00
• Potential Upside/Downside: -6.5%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 6 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: 13.87
• Forward P/E Ratio: 17.72
• P/E Growth: 0.9
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: 0.62
• Current Ratio: 2.89
• Quick Ratio: 1.33

Sales & Book Value

• Annual Sales: $5.81 billion
• Price / Sales: 2.26
• Cash Flow: $3.22 per share
• Price / Cash Flow: 9.29
• Book Value: $12.04 per share
• Price / Book: 2.49

Miscellaneous

• Outstanding Shares: 437,970,000
• Free Float: 433,593,000
• Market Cap: $13.12 billion
• Optionable: Optionable
• Beta: 0.69